KDA GROUP ANNOUNCES A COLLABORATION TO INTEGRATE NEW CLINICAL ALERTS INTO THE MEDHERIZE PLATFORM TO SUPPORT THE ADOPTION OF NEXT-GENERATION SEQUENCING FOR BREAST CANCER PATIENTS
MWN-AI** Summary
KDA Group Inc. has announced a significant collaboration with AstraZeneca Canada to enhance the Medherize platform, integrating new clinical alerts to support next-generation sequencing (NGS) testing for metastatic breast cancer patients at the Hôpital du Saint-Sacrement in Québec. This collaboration, effective December 2, 2025, could extend for three years based on successful project outcomes.
NGS allows for the simultaneous analysis of multiple tumor genes, identifying actionable biomarkers that facilitate more prompt and informed treatment decisions. By incorporating targeted digital notifications into Medherize, KDA aims to enhance clinician compliance with NGS testing protocols, ensuring timely testing and clinical responses. This integration is a vital step towards promoting precision oncology practices and aligns with initiatives from the Quebec Ministry of Health to streamline practices around oral anticancer medications.
Medherize consolidates essential patient information, including lab results and clinical alerts, into a unified workflow, thus supporting healthcare professionals in their decision-making processes. The collaboration signals both parties' commitment to improving clinical care quality and patient outcomes, leveraging digital technology for effective and personalized cancer treatment.
Yves Marmet, CEO of KDA, highlighted the partnership as a critical development in Medherize’s evolution, emphasizing its role in empowering clinical teams to make better-informed decisions for cancer patients. Meanwhile, AstraZeneca’s Head of Oncology Diagnostics, Mark Oatway, expressed pride in contributing to diagnostic innovation and ensuring the timely selection of appropriate treatments.
The project, initially deployed at one hospital, is designed to serve as a model for replication across other healthcare facilities in Québec, Canada, and potentially, internationally, laying the groundwork for similar approaches to other cancer types and targeted therapies.
MWN-AI** Analysis
KDA Group Inc. (TSXV: KDA) has announced a promising collaboration with AstraZeneca Canada to enhance the Medherize platform with new clinical alerts aimed at integrating next-generation sequencing (NGS) for breast cancer patients. This strategic initiative signals a pivotal shift towards digital healthcare solutions, and investors may find significant opportunities arising from this partnership.
The integration of NGS is a cutting-edge approach that allows for comprehensive genomic testing and the identification of actionable biomarkers. This can drastically improve treatment decisions for patients with metastatic breast cancer, aligning with the broader trend of precision medicine. Given the increasing emphasis on personalized care, KDA's role in facilitating timely access to genomic information through Medherize positions it well within a growing market.
As this collaboration targets both local and potentially broader markets—starting from Hôpital du Saint-Sacrement and aiming for replication across other healthcare institutions in Canada and beyond—investors could see KDA leveraging economies of scale and enhancing its market share. Notably, the partnership aligns with the Quebec Ministry of Health's framework, enhancing its credibility and regulatory compliance.
From a financial perspective, although this collaboration is currently classified as non-material, the potential for future revenue growth through extended contracts is significant. The phased approach to expanding NGS adoption through workflow integration can lead to sustained demand for KDA's digital solutions.
Investors should closely monitor the outcomes of this collaboration, as successful results may not only solidify KDA's position in healthcare technology but also positively influence its stock performance. Continuous innovation and partnerships in the biopharma space remain key drivers for market success. Overall, KDA's strategic direction appears promising, warranting a cautious but optimistic outlook for potential investors.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Canada NewsWire
THETFORD MINES, QC, Dec. 22, 2025 /CNW/ - KDA Group Inc. (TSXV: KDA) ("KDA" or the "Corporation"), a leader in innovative technological solutions for healthcare professionals, is pleased to announce a collaboration with AstraZeneca Canada to support the utility of next-generation sequencing ("NGS") diagnostic testing for patients with metastatic breast cancer at Hôpital du Saint-Sacrement (CHU de Québec – Université Laval). NGS enables parallel analysis of multiple tumor genes to identify clinically actionable biomarkers and support faster, more informed treatment decisions.
The collaboration agreement is non-material, is made effective as of December 2, 2025, and provides for an initial term that may be extended to three years should the project demonstrate successful outcomes.
This initiative will be delivered through Medherize, KDA's digital platform, integrated with the Québec Health Record (Dossier Santé Québec – "DSQ"). Medherize consolidates laboratory results, clinical alerts and patient-reported information into a single workflow for clinicians. By facilitating timely access to genomic testing, the project advances evidence-based practice and helps ensure patients receive timely, safe and personalized care.
The collaboration agreement aims to integrate targeted digital notifications (alerts) within Medherize to support clinicians in optimizing compliance with NGS testing, in alignment with appropriate clinical milestones. These alerts are intended to prompt timely testing, interpretation, and clinical action, thereby supporting consistent adoption of precision oncology practices across the care continuum.
This approach also aligns with the Quebec Ministry of Health and Social Services' new framework aimed at optimizing the practices of community pharmacists regarding oral anticancer medications (OAMs). The framework outlines responsibilities, including: assessment of the clinical situation, analysis of treatments based on laboratory results, patient education and follow-up plans, detection and management of treatment-related challenges and adverse effects, and ensures continuity of care with other healthcare professionals. Medherize supports these activities by connecting pharmacists to relevant DSQ information, enabling automatic receipt of laboratory results and surfacing clinical alerts and patient reported adverse events to facilitate consistent follow-up.
"This collaboration with AstraZeneca represents a significant milestone in the evolution of Medherize. It confirms the relevance of our approach, which leverages digital technology to provide concrete support to clinical teams and improve the quality of care delivered to patients. Our priority remains enabling better-informed clinical decisions, at the right time, in the direct interest of people affected by cancer," said Yves Marmet, President and Chief Executive Officer of Groupe Technologique KDA inc.
"We're proud to invest in partnerships that drive diagnostic innovation and facilitate clinical deployment of genomic testing to ultimately, help patients receive the right treatment at the right time," said Mark Oatway, Head of Oncology Diagnostics, AstraZeneca Canada. "By integrating digital workflows with next-generation sequencing, this collaboration will support faster turnaround from advanced diagnostic testing to treatment selection and more consistent, biomarker?informed care."
Initially deployed at Hôpital du Saint-Sacrement, the project is designed as a reproducible model that can be extended to other healthcare institutions in Québec, across Canada, and internationally. The same approach can also be applied to other cancer types and emerging classes of targeted therapies
ABOUT KDA GROUP
KDA Group is a leader in technological innovations and specialized software solutions (SaaS – Software as a Service) for the healthcare professionals' market. KDA is a corporation that offers high-quality products and has recognized and respected expertise among the various stakeholders in the pharmaceutical and medical sectors. The technology products developed by KDA aim, among other things, to accelerate the healthcare's digital transformation, and are available for the Canadian and international markets. Additional information about the Corporation is available at www.groupkda.com and on SEDAR+ at www.sedarplus.ca.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release from KDA Group contains forward-looking statements. Forward-looking statements are typically identified by the words assumption, goal, guidance, objective, outlook, strategy, target, and other similar expressions, or future or conditional verbs such as aim, anticipate, believe, predict, could, expect, intend, may, plan, seek, should, strive, and will. By their nature, forward-looking statements require us to make estimates and assumptions and express opinions based on current conditions and anticipated developments, as well as other factors that Management may deem appropriate under the circumstances. There is inherent uncertainty and significant risk in these estimates, assumptions, and opinions, particularly of a commercial, economic, and competitive nature, and they are therefore subject to change. KDA Group cannot guarantee that these estimates, assumptions, and opinions will prove to be accurate.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
SOURCE KDA Group Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/December2025/22/c5639.html
FAQ**
How will the collaboration between KDA Group Inc. KDA:CC and AstraZeneca Canada enhance the Medherize platform's ability to support timely genomic testing for metastatic breast cancer patients?
What specific clinical milestones will the digital alerts integrated into Medherize target to optimize compliance with next-generation sequencing testing for breast cancer patients?
Given the potential for expansion, how does KDA Group Inc. KDA:CC plan to replicate the success of the initial implementation at Hôpital du Saint-Sacrement in other healthcare institutions in Québec and beyond?
What are the anticipated measurable outcomes KDA Group Inc. KDA:CC intends to achieve through this collaboration that could validate the extension of the project beyond the initial term of three years?
**MWN-AI FAQ is based on asking OpenAI questions about Kda Group Inc. (TSXVC: KDA:CC).
NASDAQ: KDA:CC
KDA:CC Trading
-4.55% G/L:
$0.105 Last:
2,500 Volume:
$0.11 Open:
